10-K: Annexon files 10-K, advances GBS, GA programs

Annexon posted a $206.7M 2025 net loss, filed an EMA MAA for GBS, guided to a 2026 U.S. BLA and GA Phase 3 topline in 4Q26, and added a new $150M ATM financing facility.

Summary

• Reported 2025 net loss of $206.7M (vs. $138.2M in 2024) on zero product revenue; R&D $184.7M (+55%), G&A $31.7M (-8%).
• Cash, cash equivalents and short-term investments were $238.3M at 12/31/25; management expects runway into 2H 2027.
• Shares outstanding: 149.4M at 12/31/25; 160.5M at 3/25/26; 42.3M pre-funded warrants and 6.88M common warrants outstanding at 12/31/25.
• Tanruprubart (GBS): Phase 3 met primary endpoint at 30 mg/kg (p=0.0058); EMA MAA filed Jan 2026; U.S. FORWARD open-label study ongoing to support 2026 BLA; Fast Track and Orphan designations (FDA) and Orphan (EMA).
• Vonaprument (GA): Phase 2 showed significant vision preservation; Phase 3 ARCHER II enrolled 659 patients (Jul 2025); topline planned 4Q 2026; PRIME designation and EMA development support.
• ANX1502 (oral C1s inhibitor): Phase 1 completed; CAD proof-of-concept ongoing with an update planned in 2026.
• Capital actions: Nov 2025 follow-on raised ~$80.5M net; Jun 2024 raised ~$116.8M net; active 2024 ATM ($27.4M 2025 proceeds; ~$66.9M capacity at 12/31/25; ~$32.8M sold post year-end); new $150M ATM signed Mar 30, 2026.
• Accumulated deficit $917.4M; operating cash outflow $186.4M in 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as modestly positive: strong GBS Phase 3 and EMA filing, a clear 2026 catalyst path, and adequate runway; offset by widening losses, regulatory generalizability risk, and continued equity reliance.

Positives

• Clinically meaningful Phase 3 win for tanruprubart in GBS at 30 mg/kg (primary endpoint p=0.0058; early strength gains and fewer ventilation days).
• Regulatory momentum: EMA MAA filed for GBS (Jan 2026); plan to file U.S. BLA in 2026 after FORWARD data.
• Vonaprument holds PRIME designation; Phase 3 ARCHER II fully enrolled with high-value functional endpoint (confirmed 15-letter BCVA loss).
• Cash runway guided into 2H 2027, reducing near-term financing pressure.
• Multiple non-dilutive catalysts in 2026: FORWARD data to support BLA, ARCHER II topline in 4Q 2026, ANX1502 CAD update.

Negatives

• 2025 net loss widened to $206.7M; R&D spend surged (+55%) driven by manufacturing, ARCHER II and FORWARD execution.
• Tanruprubart 75 mg/kg dose did not meet the primary endpoint (p=0.5548), underscoring dose-window sensitivity.
• No approved products; continued dependence on capital markets despite cash runway.
• Regulatory risk: U.S. BLA relies on ex-U.S. pivotal data supplemented by open-label Western data; FDA may require more evidence.
• GA Phase 2 primary anatomic endpoint (lesion growth slope at 12 months) was not statistically significant, despite functional benefits.

Risks

• Substantial additional financing may be required if operating plans change; reliance on equity programs including ATMs could dilute shareholders.
• FDA may not accept generalizability of ex-U.S. GBS data; FORWARD data may be insufficient for BLA approval.
• Clinical, regulatory and manufacturing risks across late-stage programs; potential trial delays and safety events could impair timelines.
• Pricing, reimbursement and healthcare policy changes (e.g., Medicare negotiation, Most-Favored-Nation concepts) could pressure future economics.
• Cybersecurity and third‑party vendor risks; 2025 service provider incidents investigated (not material) but environment remains active.

Future Outlook

Management plans to: (1) deliver initial FORWARD (U.S./EU) GBS data in 2026 and pursue a U.S. BLA for tanruprubart in 2026; (2) report ARCHER II Phase 3 GA topline in 4Q 2026 for vonaprument; and (3) provide an ANX1502 CAD proof-of-concept update in 2026. Cash is expected to fund operations into the second half of 2027, supplemented by active ATM programs as needed.

Management Comments

• Advancing tanruprubart toward first potential approval in GBS; EMA MAA submitted in January 2026 and plan to engage FDA for a 2026 BLA following FORWARD data.
• Vonaprument is positioned as a vision-preserving GA therapy with Phase 3 ARCHER II topline planned for 4Q 2026 under a single-study U.S./EU registration strategy.
• We are building a portfolio around classical complement inhibition, including the first-in-kind oral C1s inhibitor ANX1502, with a CAD update expected in 2026.
• Existing capital resources are expected to fund planned operating expenses into the second half of 2027.

Industry Context

StockSavvy.ai notes Annexon is pursuing a differentiated upstream classical complement approach (C1q/C1s) across neuroinflammatory indications. In GBS, current standards (IVIg/plasma exchange) lack robust evidence, and Alexion’s Soliris failed its Japan Phase 3, highlighting unmet need and risk. In GA, Syfovre (C3) and Izervay (C5) are U.S.-approved but have anatomic endpoints; vonaprument targets vision preservation with functional endpoints, potentially carving out a niche if Phase 3 confirms efficacy.

Comparison to Industry Standards

• Cash runway into 2H 2027 aligns favorably with many late‑stage biotechs (e.g., Apellis pre-approval runways) but high 2025 cash burn (~$186M) implies continued reliance on equity tools like ATMs.
• GBS regulatory strategy mirrors other ex‑U.S. pivotal programs; however, FDA generalizability requirements have tripped peers (e.g., need for confirmatory Western data) — Annexon’s FORWARD dataset could be pivotal.
• GA competitive set: Apellis (pegcetacoplan, C3) and Astellas/Iveric (avacincaptad pegol, C5) achieved U.S. approvals based largely on anatomic endpoints, while vonaprument is emphasizing functional vision preservation (BCVA/LLVA) — a higher clinical bar but potentially more meaningful differentiation if successful.
• Dose-window sensitivity in GBS (30 mg/kg outperforming 75 mg/kg on primary endpoint) underscores the importance of precision dosing compared to downstream complement inhibitors.
• Oral classical complement (ANX1502) would be first-in-class vs. alternative/lectin pathway oral competitors (e.g., Novartis iptacopan factor B); early PK/PD signals are promising but require clinical validation.

Corporate Governance

Legal Proceedings

• No material legal proceedings disclosed; routine matters could arise in the ordinary course.

Related Party Transactions

• December 2023 financing included a ~$1.0M purchase (350,000 shares) by an entity related to a director.
• June 2025 warrant amendment covered 613,497 common warrants held by a board member; related deemed dividend of ~$0.2M.

Stakeholder Impact

• Shareholders: Dilution from recent financings and ATMs; additional potential dilution from pre-funded and common warrants and new $150M ATM.
• Patients: Potential first targeted GBS therapy and a vision-preserving GA therapy could address significant unmet needs.
• Employees: Expanded late-stage programs and regulatory filings may support organizational growth; equity programs provide alignment.
• Suppliers/CMOs: Increased manufacturing activity for registrational packages and potential launch readiness.
• Creditors: Adequate liquidity for near-term obligations with runway into 2H 2027.

Next Steps

• Obtain EMA decision on the tanruprubart MAA for GBS (timing not provided).
• Generate initial FORWARD (U.S./EU) data to support U.S. BLA filing for GBS in 2026.
• Report vonaprument ARCHER II Phase 3 topline in 4Q 2026.
• Provide ANX1502 CAD proof-of-concept update in 2026.
• Utilize ATM programs opportunistically to extend runway.

Key Dates

Recommendation

The late-stage pipeline and EMA filing create meaningful upside optionality, but FDA generalizability risk for GBS, a binary GA Phase 3 in 4Q26, and ongoing dilution via ATMs temper the risk-reward. Maintaining a hold stance balances strong catalysts and cash runway against regulatory and financing overhangs.

Keywords

Annexon, tanruprubart, vonaprument, ANX1502, C1q inhibition, complement pathway, Guillain-Barré syndrome, geographic atrophy, GA, AMD, EMA MAA, BLA, PRIME, Fast Track, orphan drug, pre-funded warrants, ATM offering, R&D expenses